Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists for Parkinson's Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Hassan Waseem1, Zain Abideen2, Rowaid Ahmad3, Muhammad Ansari3, Sania Aimen4, Marium Khan5
1Allama Iqbal Medical College, Lahore, Pakistan, 2King Edward Medical University, Lahore, Pakistan, 3University of Texas Medical Branch Galveston Texas, 4Quetta Institute of Medical Sciences, Pakistan, 5Jinnah Sindh Medical University, Karachi, Pakistan
Objective:

To evaluate the efficacy and safety of Glucagon-like peptide-1 (GLP-1) receptor agonists for Parkinson's disease (PD).

Background:
PD is a progressive neurodegenerative disorder leading to significant disability, with no approved disease-modifying treatments, only symptomatic relief. GLP-1 receptor agonists, used for diabetes by targeting the pancreas and insulin release, also act on brain GLP-1 receptors. Since PD patients show insulin resistance with diabetes as a risk factor, these drugs may influence PD outcomes.
Design/Methods:

PubMed, Scopus, and Cochrane Central were searched till September 2024. Risk ratios (RR) and Mean Difference (MD) with a 95% Confidence Interval (CI) were pooled for dichotomous and continuous outcomes using the Review Manager version 5.4.1. employing the random effects model. The quality of the included studies was assessed using the Cochrane RoB 2.0 tool.

Results:

Four randomized trials pooling 425 patients were included in this analysis. Compared to the placebo, GLP-1 receptor agonists significantly decreased MDS-UPDRS III score (off medication) (WMD= -3.29; 95%CI: [-5.14, -1.43]; p=0.0005; I2=0%) and increased the GI adverse event profile (RR: 1.85 [1.14, 3.01]; p=0.01; I2=0%). Other outcomes like the MDS-UPDRS I score (WMD= -0.34; 95%CI:[-1.53,0.85]; p=0.58; I2=52%), MDS-UPDRS II score (WMD= -0.18 ; 95%CI:[-1.04,0.68]; p=0.68; I2=20%), MDS-UPDRS III score (on medication) (WMD= -2.78; 95%CI:[-5.99,0.42]; p=0.09; I2=81%), MDS-UPDRS IV score (WMD= -0.06; 95%CI:[-0.41,0.28]; p=0.72; I2=0%), HRQoL (WMD= -0.58; 95%CI:[-2.32,1.16]; p=0.51; I2=0%); Mattis DRS score (WMD= 3.66; 95%CI:[-1.02,8.35]; p=0.12; I2=82%), MADRS score (WMD=-1.03 ; 95%CI:[-2.54,0.47]; p=0.18; I2=0%), serious adverse events (RR=1.50, 95%CI:[0.56,4.04]; p=0.42; I2= 9%) and weight loss (WMD= 2.17 ; 95%CI:[0.60,7.76]; p=0.24; I2=58%) were comparable between the two groups.

Conclusions:

According to our analysis, GLP-1 receptor agonists are a potentially effective therapy for Parkinson's disease, with improvements seen in MDS-UPDRS III score but with a worse GI safety profile. More trials are needed to reach a definitive conclusion.

10.1212/WNL.0000000000211906
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.